- Home
- LDP vs XERS Comparison
LDP vs XERS Comparison
Compare LDP & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- XERS
- Stock Information
- Founded
- LDP 2012
- XERS 2005
- Country
- LDP United States
- XERS United States
- Employees
- LDP N/A
- XERS N/A
- Industry
- LDP Finance Companies
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- LDP Finance
- XERS Health Care
- Exchange
- LDP Nasdaq
- XERS Nasdaq
- Market Cap
- LDP 607.2M
- XERS 509.9M
- IPO Year
- LDP N/A
- XERS 2018
- Fundamental
- Price
- LDP $20.43
- XERS $3.49
- Analyst Decision
- LDP
- XERS Buy
- Analyst Count
- LDP 0
- XERS 3
- Target Price
- LDP N/A
- XERS $4.87
- AVG Volume (30 Days)
- LDP 102.5K
- XERS 1.7M
- Earning Date
- LDP 01-01-0001
- XERS 11-08-2024
- Dividend Yield
- LDP 7.91%
- XERS N/A
- EPS Growth
- LDP N/A
- XERS N/A
- EPS
- LDP N/A
- XERS N/A
- Revenue
- LDP N/A
- XERS $187,361,000.00
- Revenue This Year
- LDP N/A
- XERS $23.48
- Revenue Next Year
- LDP N/A
- XERS $18.69
- P/E Ratio
- LDP N/A
- XERS N/A
- Revenue Growth
- LDP N/A
- XERS 22.72
- 52 Week Low
- LDP $16.16
- XERS $1.69
- 52 Week High
- LDP $20.30
- XERS $3.87
- Technical
- Relative Strength Index (RSI)
- LDP 35.63
- XERS 55.91
- Support Level
- LDP $20.12
- XERS $3.17
- Resistance Level
- LDP $21.15
- XERS $3.63
- Average True Range (ATR)
- LDP 0.28
- XERS 0.19
- MACD
- LDP -0.09
- XERS -0.02
- Stochastic Oscillator
- LDP 22.46
- XERS 45.71
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.